Clovis Oncology (CLVS) Shares are Down -2.93%

Clovis Oncology (CLVS) has risen sharply, recording gains of 54.06% in the past 4 weeks. However, the stock has corrected -2.93% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 54.89% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 15.9% and the 50-Day Moving Average is 56.86%.The 200 Day SMA reached 81.68%


Clovis Oncology (NASDAQ:CLVS): After opening at $34.65, the stock dipped to an intraday low of $33.88 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $36.15 and the buying power remained strong till the end. The stock closed at $36.05 for the day, a gain of 4.07% for the day session. The total traded volume was 2,246,205. The stocks close on the previous trading day was $36.05.

Clovis Oncology (CLVS) : 5 investment research analysts covering Clovis Oncology (CLVS) have an average price target of $33.6 for the near short term. The highest target price given by the Brokerage Firm to the stock is $50 and the lowest target is $14 for the short term. Analysts expect the variance to be within $15.01 of the average price.

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *